NYC Builds Bio+ in Collaboration with Genetic Engineering & Biotechnology News
Click Here to view the event presentation.
Click Here to view the event recording.
Click Here to view the event program.
As the threat of the novel coronavirus continues to grow globally, innovative biopharmaceutical companies and academic institutions are ramping up efforts to study the virus and develop vaccines and antivirals.
The development pipeline for COVID-19 now includes more than 160 candidate drug treatments and vaccines. Of the 70 vaccine candidates, vaccines from Moderna, Inovio Pharmaceuticals and CanSino Biologics and the Beijing Institute of Biotechnology are already being tested in humans.
NYC Builds BIO+ and Genetic Engineering & Biotechnology News (GEN) hosted an in-depth look at the vaccines and treatments under development and hear from the New York companies and institutions that are actively working on vanquishing the virus.
Agenda
1:00 PM – 1:10 PM Welcome and Overview of the Meeting
- Nancy J Kelley, President & CEO, Nancy J Kelley + Associates, Steering Committee, NYC Builds BIO+
1:10 PM – 1:50 PM Panel Presentation
MODERATOR:
- Nancy J Kelley, President & CEO, Nancy J Kelley + Associates, Steering Committee, NYC Builds BIO+
INVITED SPEAKERS:
- Alex Philippidis, Senior News Editor, Genetic Engineering & Biotechnology News
- David Weinreich, Senior Vice President, Head, Global Clinical Development, Regeneron Pharmaceuticals Inc.
- Erik Lium, PhD, President, Mount Sinai Innovation Partners
- Seth Lederman, MD, Co-Founder, CEO & Chairman, Tonix Pharmaceuticals
1:50 PM – 2:00 PM Q&A With Audience